A Banner Moment For Alzheimer's Positions Eisai/Biogen At The Head Of The Pack

More Data To Be Reported At CTAD In November

Eisai and Biogen, who have an accelerated approval decision pending in the US, said they will seek traditional approvals for lecanemab by Q1 2023 based on positive results from the Phase III Clarity AD trial.

Wolf pack with alpha and full moon concept
Lecanemab is the first of three near-term anti-amyloid readouts • Source: Shutterstock

Eisai Co., Ltd. and Biogen, Inc. have accomplished something that no other pharmaceutical company has done before – they demonstrated that an anti-amyloid antibody can improve cognition and function in Alzheimer's patients in a Phase III trial.

More from Clinical Trials

More from R&D